Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS

ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas

The evolving treatment landscape in immune thrombocytopenia

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer

Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups

Epcoritamab improves progression-free survival in relapsed or refractory large B-cell lymphoma

Favezelimab plus pembrolizumab improves progression-free survival in PD-1-refractory classic Hodgkin lymphoma

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

ASCO 2026: Lung cancer roundup

ASCO 2026: Highlights and analysis